Literature DB >> 7628934

Case-control study of risk factors for development of pleuropneumonia in horses.

S M Austin1, J H Foreman, L L Hungerford.   

Abstract

Risk factors for development of pleuropneumonia were determined by reviewing medical records of 45 horses with pleuropneumonia and 180 control horses examined between Jan 1, 1980 and Jan 1, 1990. Factors considered included age, breed, sex, occupation, transport farther than 500 miles within the previous week, racing within the previous 48 hours, viral respiratory tract infection or exposure to horses with viral respiratory tract disease within the previous 2 weeks, and vaccination against influenza or rhinopneumonitis within the previous 6 months. Results indicated that Thoroughbreds were at a greater risk of developing pleuropneumonia than were other horses, and Standardbreds were at a reduced risk. Transport farther than 500 miles and viral respiratory tract disease or exposure to horses with respiratory tract disease were determined to be risk factors for the development of pleuropneumonia.

Entities:  

Mesh:

Year:  1995        PMID: 7628934

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  11 in total

1.  Combination of medical and surgical therapy for pleuropneumonia in a horse.

Authors:  J Dechan
Journal:  Can Vet J       Date:  1997-08       Impact factor: 1.008

2.  Welfare of equidae during transport.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; Jose Luis Gonzales Rojas; Christian Gortázar Schmidt; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Helen Clare Roberts; Hans Spoolder; Karl Stahl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Bernadette Earley; Sandra Edwards; Luigi Faucitano; Sonia Marti; Genaro C Miranda de La Lama; Leonardo Nanni Costa; Peter T Thomsen; Sean Ashe; Lina Mur; Yves Van der Stede; Mette Herskin
Journal:  EFSA J       Date:  2022-09-07

3.  Cryptococcus gattii pneumonia in an adult horse which had travelled in an endemic area.

Authors:  Marion Allano; Carolyn Grimes; Roxane Boivin; Glenn Smith; Jeannot Dumaresq; Mathilde Leclere
Journal:  Can Vet J       Date:  2019-12       Impact factor: 1.008

4.  Supplementation of Ascorbic Acid in Weanling Horses Following Prolonged Transportation.

Authors:  Sarah Ralston; Michelle Stives
Journal:  Animals (Basel)       Date:  2012-04-16       Impact factor: 2.752

5.  Health Problems and Risk Factors Associated with Long Haul Transport of Horses in Australia.

Authors:  Barbara Padalino; Evelyn Hall; Sharanne Raidal; Pietro Celi; Peter Knight; Leo Jeffcott; Gary Muscatello
Journal:  Animals (Basel)       Date:  2015-12-10       Impact factor: 2.752

6.  A Survey on Transport Management Practices Associated with Injuries and Health Problems in Horses.

Authors:  Barbara Padalino; Sharanne L Raidal; Evelyn Hall; Peter Knight; Pietro Celi; Leo Jeffcott; Gary Muscatello
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

7.  Behaviour during transportation predicts stress response and lower airway contamination in horses.

Authors:  Barbara Padalino; Sharanne L Raidal; Peter Knight; Pietro Celi; Leo Jeffcott; Gary Muscatello
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

8.  Factors Associated with Survival in 97 Horses with Septic Pleuropneumonia.

Authors:  M G Arroyo; N M Slovis; G E Moore; S D Taylor
Journal:  J Vet Intern Med       Date:  2017-03-08       Impact factor: 3.333

9.  Patterns of Rectal Temperature and Shipping Fever Incidence in Horses Transported Over Long-Distances.

Authors:  Yousuke Maeda; Masa-Aki Oikawa
Journal:  Front Vet Sci       Date:  2019-02-14

10.  First isolation of Klebsiella variicola from a horse pleural effusion.

Authors:  Elisabetta Mondo; Riccardo Rinnovati; Alessandro Spadari; Federica Giacometti; Andrea Serraino; Federica Savini; Silvia Piva
Journal:  BMC Vet Res       Date:  2021-02-12       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.